Aitia
Isabelle Caffry is an accomplished professional in the field of strategy and corporate development. With a strong educational background in chemistry and chemical engineering, Isabelle has gained extensive experience working in various research and business development roles in companies like Adimab, Evelo Biosciences, and EY-Parthenon. Currently serving as the Senior Director of Strategy & Corporate Development at Aitia, Isabelle's diverse skill set and expertise make their a valuable asset to the organization.
Aitia
1 followers
Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.